BRISBANE, Calif., May 8 /PRNewswire-FirstCall/ -- VaxGen, Inc.
WHAT: Senior Vice President, Research & Development, Kathrin Jansen, Ph.D., will give a presentation titled “Potency and Stability of a Recombinant Anthrax (rPA) Vaccine” as part of a panel session at the 9th Annual Conference on Vaccine Research sponsored by the National Foundation for Infectious Diseases in Baltimore, Md. WHEN/ WHERE: The panel session takes place from 11:00 a.m. to noon, ET Wednesday, May 10, 2006 Baltimore Marriott Inner Harbor Hotel, Baltimore About VaxGen
VaxGen, Inc. is a biopharmaceutical company engaged in the development, manufacture and commercialization of biologic products for the prevention and treatment of human infectious diseases, including anthrax and smallpox. VaxGen has been awarded an $877.5 million contract by the U.S. Department of Health and Human Services to provide 75 million doses of a recombinant anthrax vaccine for civilian biodefense. Based in Brisbane, Calif., VaxGen operates a wholly-owned manufacturing facility in California and owns 21% of Celltrion, Inc., a company in the Republic of Korea established to provide contract manufacturing to the global pharmaceutical industry. For more information, please visit the company’s web site at www.vaxgen.com.
(Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO)
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk photodesk@prnewswire.comVaxGen, Inc.
CONTACT: Pat Beaupre Becker of VaxGen, Inc., +1-650-624-1041
Web site: http://www.vaxgen.com//
